Supporting Information

Total Page:16

File Type:pdf, Size:1020Kb

Supporting Information Supporting Information Galan et al. 10.1073/pnas.1405601111 SI Experimental Procedures Sample Preparation and Trypsin Digestion. Cells were lysed in 1% GST-14-3-3 Fusion Proteins, Subtractive Fractionation, and Pull-Down sodium deoxycholate in 50 mM ammonium bicarbonate (pH 7.8) Assays. Fifty milliliters of overnight cultures of BL21 Escherichia and heated to 99 °C for 5 min. The mixture was then allowed to coli transformed with pGEX-4T-14-3-3e WT or K49E mutant cool down on ice and centrifuged at 13,000 × g for 10 min 5 mM were diluted into 500 mL and culture was induced with 1 mM DTT was added to the supernatant and incubated for 30 min at isopropyl β-D-1-thiogalactopyranoside overnight at 25 °C. Cells 56 °C, followed by alkylation with 15 mM iodoacetamide for 1 h were pelleted and resuspended in 40 mL of bacterial lysis buffer at 25 °C in the dark. Excess iodoacetamide was neutralized using (1× PBS/10 mM EDTA/0.1% Triton X, 1 mM PMSF, and 1× 5 mM DTT incubated for 15 min at 25 °C. Proteins were digested protease inhibitor mixture). Extracts were placed in a 50-mL overnight with sequencing-grade modified trypsin (enzyme: conical tube on ice and sonicated using a probe sonicator six protein ratio of 1:50) at 37 °C. The digested mixture was acid- times for 30 s with 30-s delays between blasts. After sonication, ified with 1% formic acid (FA) final concentration. The samples the extracts were centrifuged at 13,000 × g for 30 min and ali- were desalted using C18 (Waters) cartridge following the manufacturer’s instructions and then evaporated to dryness in a quoted into 1-mL tubes to be stored at −80 °C until further use. SpeedVac. For subtractive fractionation, we used a method previously de- scribed (1). Briefly, serum-starved A375 cells were lysed as de- Phosphopeptide Isolation, Offline Strong Cation Exchange Fractionation, scribed above. Cellular debris were removed by centrifugation for and Nanoflow Liquid Chromatography-MS/MS. The peptide samples 10 min at 13,000 × g. The supernatant, corresponding to 20 mg of were subjected to the TiO2 enrichment protocol as described in protein, was precleared by pouring it sequentially over glutathi- ref. 2. Briefly, sample loading, washing, and elution steps were one-Sepharose (GE/Amersham/Pharmacia), glutathione-Sephar- performed in homemade spin columns assembled following the ose bound to 500 μg of GST, and glutathione-Sepharose bound StageTip principle (3, 4) and composed of a 200-μL pipette tip with μ e to 250 g of GST-14-3-3 K49E. The flow-through was divided frit made of SDB-XC membrane (3M) and filled with TiO2 beads. equally and poured over GST-14-3-3e K49E (250 μg) or GST- SDB-XC material has similar hydrophobic properties to C18 and 14-3-3e WT (250 μg) (as shown in the schematic of Fig. 4A). The allows for combining phosphopeptide enrichment and desalting beads were then washed two times with 2 mL lysis buffer and steps. Centrifugation speed was set to 2,000 × g. Before peptide a final wash of 2 mL of lysis buffer lacking Nonidet P-40 and Brij loading, columns were equilibrated with 100 μL of loading buffer 35. Cellular proteins bound to each column were eluted stepwise [250 mM lactic acid in 70% acetonitrile (ACN) and 3% TFA]. μ with 400 μL of 400 mM MgCl2 in 50 mM Hepes, 400 μLof Peptides were solubilized in 100 L of loading buffer and applied μ 800 mM MgCl2 in 50 mM Hepes, and finally chased with 200 μL on a TiO2 column. Each column was washed with 100 Lof of 50 mM Hepes. Eluates were combined and precipitated with loading buffer followed by 2 × 100 μL of 125 mM asparagine and 15% trichloroacetic acid. Precipitated proteins were pelleted, glutamine in 70% ACN and 3% TFA and 100 μL of 70% ACN μ washed with acetone, resuspended in reducing sample buffer, and 3% TFA. Subsequent washing with 50 Lof1%FAwasused pH-adjusted with one-sixth volume of 1 M Tris base, boiled, and to equilibrate SDB-XC frit material. Phosphopeptides were × μ subjected to SDS/PAGE for Coomassie staining or immuno- eluted from TiO2 with 2 50- L portions of 500 mM Na2HPO4, blotting. For smaller-scale GST pull-downs, cell lysates were in- pH 7, and retained on SDB-XC frit. Peptides were desalted in 50 μ μ cubated with 10 μg of GST-14-3-3e WT or K49E for 2 h and L of 1% FA and subsequently eluted from SDB-XC in 50 Lof 50% ACN and 0.5% FA. Eluates were dried on a speedvac and washed four times with lysis buffer before elution with reducing − sample buffer, SDS/PAGE, and immunoblotting. stored at 80 °C. To increase phosphoproteome coverage before MS analysis, Stable Isotope Labeling by Amino Acids in Cell Culture. HEK293 and phosphopeptides were fractionated offline by strong cation ex- 12 14 12 14 change (SCX) chromatography. Peptides were solubilized in 100 A375 cells were grown in light ([ C6 N2]Lys, [ C6 N4]Arg) 13 15 13 15 μL of loading buffer (0.2% FA and 15% ACN) and loaded onto and heavy ([ C6 N2]Lys, [ C6, N4]Arg) DMEM (Cambridge Isotope Labs) where required. Both light and heavy cell types StageTips containing 6 mg of PolySULFOETHYL A SCX phase (5 μm, 300 angstrom). Then columns were washed with were supplemented with 10% dialyzed fetal bovine serum (In- μ vitrogen). For the use of pharmacological inhibitors, HEK293 an additional 50 L of the loading buffer and peptides were eluted in 100-μL salt steps with 40, 70, 100, 150, and 500 mM cells were serum-starved for 24 h and cells cultured in heavy NaCl dissolved in loading buffer. Flow-through and salt fractions media were treated with PD184352 (10 μM) or BI-D1870 were collected, dried on a speedvac, resuspended in 15 μLof4% (10 μM) for 30 min followed by phorbol-12-myristate-13-acetate FA, and analyzed by nano liquid chromatography-MS/MS. (PMA) (50 ng/mL) treatment for 30 min in both light and heavy SCX fractions obtained after offline fractionation were analyzed conditions. In A375 cells, cells were serum-starved for 24 h and by online reverse-phase chromatography coupled with an elec- μ μ treated with PD184352 (10 M) or BI-D1870 (10 M) for 2 h in trospray ionization interface to acquire MS (measuring intensity the heavy media. For the use of shRNA to target RSK1/2, and m/z ratio for peptides) and MS/MS (fragmentation spectra of HEK293 cells in heavy media were virally infected as described peptides) scans. A nanoflow HPLC system (Eksigent; Thermo above, serum-starved for 24 h, and stimulated with PMA (50 ng/ Fisher Scientific) was used for online reversed-phase chromato- mL) treatment for 30 min in both light and heavy conditions. graphic separation; peptides were loaded on a 5-mm-long trap A375 cells in heavy media were virally infected as described column (inner diameter 300 μm) in buffer A (0.2% FA) and above and serum-starved for 24 h. We performed two biological separated on 18-cm-long fused silica capillary analytical column replicates for each experimental design detailed above with (inner diameter 150 μm), both packed with 3 μm 200 Å Magic cross-labeling (changing the treatment condition on the light AQ C18 reverse-phase material (Michrom). Peptides were eluted cultured cells instead of heavy cultured cells) without significant by an increasing concentration of buffer B (0.2% FA in ACN) differences. from 5 to 40% in 100 min. Following the gradient elution, the Galan et al. www.pnas.org/cgi/content/short/1405601111 1of10 column was washed with 80% buffer B and reequilibrated with also added to the database as well as reversed versions of all 5% buffer B. Peptides were eluted into the mass spectrometer at sequences. For searching, the enzyme specificity was set to a flow rate of 600 nL/min. The total run time was ∼125 min, trypsin with the maximum number of missed cleavages set to 2. including sample loading and column conditioning. Peptides were The precursor mass tolerance was set to 20 ppm for the first search analyzed using an automated data-dependent acquisition on a [used for nonlinear mass recalibration (6)] and then to 6 ppm LTQ-Orbitrap Elite mass spectrometer. Each MS scan was for the main search. Search criteria included a static modifica- acquired at a resolution of 240,000 FWHM (at 400 m/z)for + mass range 300–2,000 Th with the lock mass option enabled tion of cysteine residues of 57.0214 Da; a variable modification + (m/z: 445.120025) and was followed by up to 12 MS/MS data- of 15.9949 Da to include potential oxidation of methionines; and dependent scans on the most intense ions using collision- a modification of +79.966 on serine, threonine, or tyrosine for the induced activation (CID). AGC target values for MS and MS/ identification of phosphorylation. The false discovery rate for pep- MS scans were set to 1E6 (maximum fill time 500 ms) and 1E5 tide, protein, and site identification was set to 1%, the minimum (maximum fill time 50 ms), respectively. The precursor isolation peptide length was set to 6, and the “peptide requantification” window was set to 2 Th with CID normalized collision energy of function was enabled. To transfer identifications across different 35; the dynamic exclusion window was set to 60 s. runs, the “match between runs” option in MaxQuant was enabled with a retention time window of 1 min.
Recommended publications
  • Characterization of BRCA1-Deficient Premalignant Tissues and Cancers Identifies Plekha5 As a Tumor Metastasis Suppressor
    ARTICLE https://doi.org/10.1038/s41467-020-18637-9 OPEN Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor Jianlin Liu1,2, Ragini Adhav1,2, Kai Miao1,2, Sek Man Su1,2, Lihua Mo1,2, Un In Chan1,2, Xin Zhang1,2, Jun Xu1,2, Jianjie Li1,2, Xiaodong Shu1,2, Jianming Zeng 1,2, Xu Zhang1,2, Xueying Lyu1,2, Lakhansing Pardeshi1,3, ✉ ✉ Kaeling Tan1,3, Heng Sun1,2, Koon Ho Wong 1,3, Chuxia Deng 1,2 & Xiaoling Xu 1,2 1234567890():,; Single-cell whole-exome sequencing (scWES) is a powerful approach for deciphering intra- tumor heterogeneity and identifying cancer drivers. So far, however, simultaneous analysis of single nucleotide variants (SNVs) and copy number variations (CNVs) of a single cell has been challenging. By analyzing SNVs and CNVs simultaneously in bulk and single cells of premalignant tissues and tumors from mouse and human BRCA1-associated breast cancers, we discover an evolution process through which the tumors initiate from cells with SNVs affecting driver genes in the premalignant stage and malignantly progress later via CNVs acquired in chromosome regions with cancer driver genes. These events occur randomly and hit many putative cancer drivers besides p53 to generate unique genetic and pathological features for each tumor. Upon this, we finally identify a tumor metastasis suppressor Plekha5, whose deficiency promotes cancer metastasis to the liver and/or lung. 1 Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, SAR, China. 2 Centre for Precision Medicine Research and Training, Faculty of Health Sciences, University of Macau, Macau, SAR, China.
    [Show full text]
  • CLASP2 Antibody Product Type
    PRODUCT INFORMATION Product name: CLASP2 antibody Product type: Primary antibodies Description: Rabbit polyclonal to CLASP2 Immunogen:3 synthetic peptides (human) conjugated to KLH Reacts with:Hu, Ms Tested applications:ELISA, WB and IF GENE INFORMATION Gene Symbol: CLASP2 Gene Name:cytoplasmic linker associated protein 2 Ensembl ID:ENSG00000163539 Entrez GeneID:23122 GenBank Accession number:AB014527 Swiss-Prot:O75122 Molecular weight of CLASP2: 165.9 & 108.6kDa Function:Microtubule plus-end tracking protein that promotes the stabilization of dynamic microtubules. Involved in the nucleation of noncentrosomal microtubules originating from the trans-Golgi network (TGN). Required for the polarization of the cytoplasmic microtubule arrays in migrating cells towards the leading edge of the cell. May act at the cell cortex to enhance the frequency of rescue of depolymerizing microtubules by attaching their plus- ends to cortical platforms composed of ERC1 and PHLDB2. This cortical microtubule stabilizing activity is regulated at least in part by phosphatidylinositol 3-kinase signaling. Also performs a similar stabilizing function at the kinetochore which is essential for the bipolar alignment of chromosomes on the mitotic spindle. Acts as a mediator of ERBB2- dependent stabilization of microtubules at the cell cortex. Expected subcellular localization:Cytoplasm › cytoskeleton. Cytoplasm › cytoskeleton › microtubule organizing center › centrosome. Chromosome › centromere › kinetochore. Cytoplasm › cytoskeleton › spindle. Golgi apparatus. Golgi apparatus › trans-Golgi network. Cell membrane. Cell projection › ruffle membrane. Note: Localizes to microtubule plus ends. Localizes to centrosomes, kinetochores and the mitotic spindle from prometaphase. Subsequently localizes to the spindle midzone from anaphase and to the midbody from telophase. In migrating cells localizes to the plus ends of microtubules within the cell body and to the entire microtubule lattice within the lamella.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • MBNL1 Regulates Essential Alternative RNA Splicing Patterns in MLL-Rearranged Leukemia
    ARTICLE https://doi.org/10.1038/s41467-020-15733-8 OPEN MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia Svetlana S. Itskovich1,9, Arun Gurunathan 2,9, Jason Clark 1, Matthew Burwinkel1, Mark Wunderlich3, Mikaela R. Berger4, Aishwarya Kulkarni5,6, Kashish Chetal6, Meenakshi Venkatasubramanian5,6, ✉ Nathan Salomonis 6,7, Ashish R. Kumar 1,7 & Lynn H. Lee 7,8 Despite growing awareness of the biologic features underlying MLL-rearranged leukemia, 1234567890():,; targeted therapies for this leukemia have remained elusive and clinical outcomes remain dismal. MBNL1, a protein involved in alternative splicing, is consistently overexpressed in MLL-rearranged leukemias. We found that MBNL1 loss significantly impairs propagation of murine and human MLL-rearranged leukemia in vitro and in vivo. Through transcriptomic profiling of our experimental systems, we show that in leukemic cells, MBNL1 regulates alternative splicing (predominantly intron exclusion) of several genes including those essential for MLL-rearranged leukemogenesis, such as DOT1L and SETD1A.Wefinally show that selective leukemic cell death is achievable with a small molecule inhibitor of MBNL1. These findings provide the basis for a new therapeutic target in MLL-rearranged leukemia and act as further validation of a burgeoning paradigm in targeted therapy, namely the disruption of cancer-specific splicing programs through the targeting of selectively essential RNA binding proteins. 1 Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 2 Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 3 Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA.
    [Show full text]
  • 1 Supporting Information for a Microrna Network Regulates
    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
    [Show full text]
  • Mouse Phldb2 Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Phldb2 Knockout Project (CRISPR/Cas9) Objective: To create a Phldb2 knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Phldb2 gene (NCBI Reference Sequence: NM_001252442 ; Ensembl: ENSMUSG00000033149 ) is located on Mouse chromosome 16. 19 exons are identified, with the ATG start codon in exon 2 and the TAG stop codon in exon 19 (Transcript: ENSMUST00000076333). Exon 2 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a conditional allele activated in neurons exhibit impaired LTP. Exon 2 starts from the coding region. Exon 2 covers 33.87% of the coding region. The size of effective KO region: ~1337 bp. The KO region does not have any other known gene. Page 1 of 9 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 19 Legends Exon of mouse Phldb2 Knockout region Page 2 of 9 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 2 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section downstream of Exon 2 is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Chemical Genetic Screen Identifies Gapex-5/GAPVD1 and STBD1 As Novel AMPK Substrates
    Chemical genetic screen identifies Gapex-5/GAPVD1 and STBD1 as novel AMPK substrates Ducommun, Serge; Deak, Maria; Zeigerer, Anja; Göransson, Olga; Seitz, Susanne; Collodet, Caterina; Madsen, Agnete Bjerregaard; Jensen, Thomas Elbenhardt; Viollet, Benoit; Foretz, Marc; Gut, Philipp; Sumpton, David; Sakamoto, Kei Published in: Cellular Signalling DOI: 10.1016/j.cellsig.2019.02.001 Publication date: 2019 Document version Publisher's PDF, also known as Version of record Document license: CC BY-NC-ND Citation for published version (APA): Ducommun, S., Deak, M., Zeigerer, A., Göransson, O., Seitz, S., Collodet, C., Madsen, A. B., Jensen, T. E., Viollet, B., Foretz, M., Gut, P., Sumpton, D., & Sakamoto, K. (2019). Chemical genetic screen identifies Gapex- 5/GAPVD1 and STBD1 as novel AMPK substrates. Cellular Signalling, 57, 45-57. https://doi.org/10.1016/j.cellsig.2019.02.001 Download date: 24. Sep. 2021 Cellular Signalling 57 (2019) 45–57 Contents lists available at ScienceDirect Cellular Signalling journal homepage: www.elsevier.com/locate/cellsig Chemical genetic screen identifies Gapex-5/GAPVD1 and STBD1 as novel AMPK substrates T Serge Ducommuna,b,1, Maria Deaka, Anja Zeigererc,d,e, Olga Göranssonf, Susanne Seitzc,d,e, Caterina Collodeta,b, Agnete B. Madseng, Thomas E. Jenseng, Benoit Violleth,i,j, Marc Foretzh,i,j, ⁎ Philipp Guta, David Sumptonk, Kei Sakamotoa,b, a Nestlé Research, École Polytechnique Fédérale de Lausanne (EPFL) Innovation Park, bâtiment G, 1015 Lausanne, Switzerland b School of Life Sciences, EPFL, 1015 Lausanne, Switzerland
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Mutation of Plekha7 Attenuates Salt-Sensitive Hypertension in the Rat
    Mutation of Plekha7 attenuates salt-sensitive hypertension in the rat Bradley T. Endresa,b, Jessica R. C. Priestleya, Oleg Palygina, Michael J. Flistera,b, Matthew J. Hoffmana, Brian D. Weinberga, Michael Grzybowskia,b, Julian H. Lombarda, Alexander Staruschenkoa, Carol Morenoa,b, Howard J. Jacoba,b,c, and Aron M. Geurtsa,b,d,1 Departments of aPhysiology and cPediatrics, bHuman and Molecular Genetics Center, and dCardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226 Edited by Richard P. Lifton, Yale University School of Medicine, New Haven, CT, and approved July 23, 2014 (received for review June 24, 2014) PLEKHA7 (pleckstrin homology domain containing family A mem- hypertension and renal injury by selective ablation of adaptive im- em1Mcwi em1Mcwi ber 7) has been found in multiple studies as a candidate gene for mune cells in the SS-Rag1 and SS-Cd247 knockout human hypertension, yet functional data supporting this associa- rats (16, 17) and reduced hypertension and renal injury in the em1Mcwi tion are lacking. We investigated the contribution of this gene SS-Ncf2 (p67phox) null model exhibiting reduced medul- to the pathogenesis of salt-sensitive hypertension by mutating lary oxidative stress (18). Additionally, we have recently demon- Plekha7 in the Dahl salt-sensitive (SS/JrHsdMcwi) rat using zinc- strated multiple genes at a single hypertension GWAS-nominated finger nuclease technology. After four weeks on an 8% NaCl diet, locus (Agtrap-Plod1 locus) can have additive or subtractive effects homozygous mutant rats had lower mean arterial (149 ± 9 mmHg on blood pressure and renal function when mutated in the SS rat vs.
    [Show full text]
  • Long-Range Chromosome Interactions Mediated by Cohesin Shape Circadian Gene Expression
    RESEARCH ARTICLE Long-Range Chromosome Interactions Mediated by Cohesin Shape Circadian Gene Expression Yichi Xu1,2, Weimin Guo1, Ping Li3, Yan Zhang3, Meng Zhao1,4, Zenghua Fan1,2, Zhihu Zhao3, Jun Yan1,4* 1 CAS-MPG Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China, 2 University of Chinese Academy of Sciences, Shanghai, China, 3 Beijing Institute of Biotechnology, Beijing, China, 4 Institute of Neuroscience, State Key Laboratory a11111 of Neuroscience, CAS Center for Excellence in Brain Science, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China * [email protected] Abstract OPEN ACCESS Mammalian circadian rhythm is established by the negative feedback loops consisting of a Citation: Xu Y, Guo W, Li P, Zhang Y, Zhao M, Fan Z, et al. (2016) Long-Range Chromosome Interactions set of clock genes, which lead to the circadian expression of thousands of downstream Mediated by Cohesin Shape Circadian Gene genes in vivo. As genome-wide transcription is organized under the high-order chromosome Expression. PLoS Genet 12(5): e1005992. structure, it is largely uncharted how circadian gene expression is influenced by chromo- doi:10.1371/journal.pgen.1005992 some architecture. We focus on the function of chromatin structure proteins cohesin as well — Editor: Achim Kramer, Charité Universitätsmedizin as CTCF (CCCTC-binding factor) in circadian rhythm. Using circular chromosome confor- Berlin, GERMANY mation capture sequencing, we systematically examined the interacting loci of a Bmal1- Received: October 10, 2015 bound super-enhancer upstream of a clock gene Nr1d1 in mouse liver. These interactions Accepted: March 27, 2016 are largely stable in the circadian cycle and cohesin binding sites are enriched in the interac- Published: May 2, 2016 tome.
    [Show full text]
  • The Use of Phosphoproteomic Data to Identify Altered Kinases and Signaling Pathways in Cancer
    The use of phosphoproteomic data to identify altered kinases and signaling pathways in cancer By Sara Renee Savage Thesis Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Biomedical Informatics August 10, 2018 Nashville, Tennessee Approved: Bing Zhang, Ph.D. Carlos Lopez, Ph.D. Qi Liu, Ph.D. ACKNOWLEDGEMENTS The work presented in this thesis would not have been possible without the funding provided by the NLM training grant (T15-LM007450) and the support of the Biomedical Informatics department at Vanderbilt. I am particularly indebted to Rischelle Jenkins, who helped me solve all administrative issues. Furthermore, this work is the result of a collaboration between all members of the Zhang lab and the larger CPTAC consortium. I would like to thank the other CPTAC centers for processing the data, and Chen Huang and Suhas Vasaikar in the Zhang lab for analyzing the colon cancer copy number and proteomic data, respectively. All members of the Zhang lab have been extremely helpful in answering any questions I had and offering suggestions on my work. Finally, I would like to acknowledge my mentor, Bing Zhang. I am extremely grateful for his guidance and for giving me the opportunity to work on these projects. ii TABLE OF CONTENTS Page ACKNOWLEDGEMENTS ................................................................................................ ii LIST OF TABLES............................................................................................................
    [Show full text]
  • Micrornas in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine
    cells Review MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine Danyel Fernandes Contiliani 1,2, Yasmin de Araújo Ribeiro 1,2, Vitor Nolasco de Moraes 1,2 and Tiago Campos Pereira 1,2,* 1 Graduate Program of Genetics, Department of Genetics, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Av. Bandeirantes, Ribeirao Preto 3900, Brazil; [email protected] (D.F.C.); [email protected] (Y.d.A.R.); [email protected] (V.N.d.M.) 2 Department of Biology, Faculty of Philosophy, Sciences and Letters, University of Sao Paulo, Av. Bandeirantes, Ribeirao Preto 3900, Brazil * Correspondence: [email protected]; Tel.: +55-16-3315-3818 Abstract: MicroRNAs (miRNAs) are small non-coding RNA molecules able to post-transcriptionally regulate gene expression via base-pairing with partially complementary sequences of target tran- scripts. Prion diseases comprise a singular group of neurodegenerative conditions caused by endoge- nous, misfolded pathogenic (prion) proteins, associated with molecular aggregates. In humans, classical prion diseases include Creutzfeldt–Jakob disease, fatal familial insomnia, Gerstmann– Sträussler–Scheinker syndrome, and kuru. The aim of this review is to present the connections between miRNAs and prions, exploring how the interaction of both molecular actors may help understand the susceptibility, onset, progression, and pathological findings typical of such disorders, as well as the interface with some prion-like disorders, such as Alzheimer’s. Additionally, due to the inter-regulation of prions and miRNAs in health and disease, potential biomarkers for non-invasive miRNA-based diagnostics, as well as possible miRNA-based therapies to restore the levels of dereg- Citation: Contiliani, D.F.; Ribeiro, Y.d.A.; de Moraes, V.N.; Pereira, T.C.
    [Show full text]